Get started
Author

Mukesh Kumar Ranjan

Observed names: M K Ranjan, M Kumar Ranjan, Mukesh K Ranjan, Mukesh K. Ranjan, Mukesh Ranjan
Observed institutions: Harvard University, Chitwan Medical College, Bir Hospital, Massachusetts General Hospital, Post Graduate Institute of Medical Education and Research, All India Institute of Medical Sciences
ORCID: 0000-0003-2575-5971
Observed ORCID: 0000-0003-2575-5971
OpenAlex ID: A5041958588
Use of thiopurines in inflammatory bowel disease: an update
2021 · Arshdeep Singh, Ramit Mahajan, et al. · Intestinal Research · 113
PDF
Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis
2021 · Pabitra Sahu, Saurabh Kedia, et al. · Alimentary Pharmacology & Therapeutics · 82
Outcome of Conservative Therapy in Coronavirus disease-2019 Patients Presenting With Gastrointestinal Bleeding
2020 · Shalimar, Manas Vaishnav, et al. · Journal of Clinical and Experimental Hepatology · 29
PDF
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
2022 · Peeyush Kumar, Sudheer K. Vuyyuru, et al. · Alimentary Pharmacology & Therapeutics · 27
Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
2022 · Mukesh Kumar Ranjan, Bhaskar Kante, et al. · Journal of Gastroenterology and Hepatology · 24
Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis
2021 · Sudheer K Vuyyuru, Saurabh Kedia, et al. · Future Microbiology · 19
Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: A cohort analysis
2020 · Sudheer K. Vuyyuru, Pabitra Sahu, et al. · Indian Journal of Gastroenterology · 17
Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
2021 · Sudheer K. Vuyyuru, Bhaskar Kante, et al. · Scientific Reports · 16
PDF
Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring
2023 · Peeyush Kumar, Sudheer K. Vuyyuru, et al. · Intestinal Research · 14
PDF
Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn’s disease in tuberculosis endemic areas
2022 · Karan Sachdeva, Peeyush Kumar, et al. · Intestinal Research · 14
PDF
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
2022 · Nagesh Kamat, Sudheer K Vuyyuru, et al. · Intestinal Research · 11
PDF
Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
2023 · Mukesh Kumar Ranjan, Peeyush Kumar, et al. · Journal of Crohn s and Colitis · 10
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
2022 · Peeyush Kumar, Sudheer K. Vuyyuru, et al. · Indian Journal of Gastroenterology · 10
Burden of Anxiety, Depression and Perceived Stress in Patients with Inflammatory Bowel Disease: A Cohort Study from North India
2024 · Arshdeep Singh, Arshia Bhardwaj, et al. · Digestive Diseases and Sciences · 9
Intravenous Albumin Infusion Does not Augment the Response Rate to a Combination of Exclusive Enteral Nutrition and Intravenous Steroids in Acute Severe Ulcerative Colitis: A Randomised Controlled Trial
2024 · Sandeep K Mundhra, Divya Madan, et al. · Journal of Crohn s and Colitis · 8
“Prevalence, Predictors, and Impact of Hepatic Steatosis in Patients With Ulcerative Colitis: A Prospective Observational Cohort Study”
2023 · Arti Gupta, Sudheer K. Vuyyuru, et al. · Journal of Clinical and Experimental Hepatology · 7
PDF
Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease
2022 · Mukesh Kumar Ranjan, Sudheer Kumar Vuyyuru, et al. · International Journal of Colorectal Disease · 7
Utility of Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis
2024 · Mukesh K Ranjan, Pradeep Neupane, et al. · Cureus · 4
PDF
Monotherapy with thiopurines in stricturing Crohn’s disease: A real-life experience from low- and middle-income countries
2022 · Bhaskar Kante, Sudheer Kumar Vuyyuru, et al. · Indian Journal of Gastroenterology · 3
Prevalence of Atrophic Gastritis in Symptomatic Patients Undergoing Gastric Biopsy in a Tertiary Care Center of Nepal
2023 · Mukesh Ranjan, Sagar Poudyal, et al. · Journal of Chitwan Medical College · 2
PDF
P1000 A quasi-experimental study evaluating effectiveness of partial enteral nutrition combined with exclusion diet in patients with mild to moderately severe ulcerative colitis
2025 · S Vuyyuru, D Madan, et al. · Journal of Crohn s and Colitis · 1
PDF
Unveiling the hidden culprit: Parathyroid adenoma induced recurrent renal calculus and pancreatitis—A case report
2024 · Aakash Kumar Pandit, Prajjwal Pokharel, et al. · Clinical Case Reports · 1
PDF
Epidemiology and Demographic Profile of Inflammatory Bowel Disease in Nepal
2023 · Mukesh K Ranjan, Rahul Pathak · Journal of Institute of Medicine Nepal · 1
PDF
P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
2022 · P Kumar, S K Vuyyuru, et al. · Journal of Crohn s and Colitis · 1
PDF
P423 Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries
2022 · M K Ranjan, P Kumar, et al. · Journal of Crohn s and Colitis · 1
Works count: 52
Citation count: 432
H-index: 11
I10-index: 13
Year
Topic
Type